The Asthma–Chronic Obstructive Pulmonary Disease Overlap...

Alvee Discussion started by Alvee 3 years ago
This in an aging population is a Addon to Asthma that all should be aware of due to the symptoms being so similar it is hard to diagnose.

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the obstructive airway diseases and patients experience worse outcomes compared with asthma or COPD alone. Patients with ACOS have the combined risk factors of smoking and atopy, are generally younger than patients with COPD and experience acute exacerbations with higher frequency and greater severity than lone COPD. Pharmacotherapeutic considerations require an integrated approach, first to identify the relevant clinical phenotype(s), then to determine the best available therapy. The authors discuss the array of existing and emerging classes of drugs that could benefit those with ACOS and share their therapeutic approach. A consensus international definition of ACOS is needed to design prospective, randomized clinical trials to evaluate specific drug interventions on important outcomes such as lung function, acute exacerbations, quality of life and mortality.

The full text of the article can be read here  https://www.medscape.com/viewarticle/780902
Replies
Osaruname Osayi-Osazuwa
Osaruname Osayi-Osazuwa It would be interesting to know and compare both outcomes of pharmaceuticals and cannabinoids among certain age groups. Cannabis has had immense... Show more 2 years ago
loader
loader
attachment
You need to be a member of this group before you can participate in this discussion.

Cannabis Science Economic Development Program

Cannabis Science Economic Development Plan

Cannabis Science Share Structure Updates

CBIS Share Structure Updates

Cannabis Science Updates

CBIS Updates

Transfer Agent

Securities Transfer Corp.

STC is regulated by the Securities and Exchange Commission

2901 N Dallas Parkway
Suite 380
Plano, Texas 75093
(469) 633-0101

Become an iCannabinoid Ambassador

GET INV

Observational Studies

PART

Activity Stream

www.accesswire.com/634059/OMNICANNAThermic-Science…

Loading content, please wait.
Bradford Patterson I'm proud to be a part of this company and our journey. Special Purpose Acquisition Company "SPAC" !!! This is Huge. 7 hours 53 minutes ago
loader
loader
Attachment
Maureen Abston Yes!!!!
This is huge!!!
7 hours 32 minutes ago
loader
loader
Attachment
Mike Chilcote Great move in acquiring this product. Looking for great things in our future 3 hours 11 minutes ago
loader
loader
Attachment

FINAL Updated CSi – First Rights DATES !!!

*** March 31, 2021 is the Last Day for the CSi First Rights offering.

We need to begin the Cannabis...
Show more

Mike Chilcote I agree with Maureens comments. I tried to keep up and answer people’s questions on the site but got tired of answering the same questions over and... Show more yesterday
loader
loader
Attachment
Bradford Patterson Thanks Maureen, for what you are doing in (re-sharing) the information. And keeping some of us up to date. You're good at that. Peace and Blessings... Show more 15 hours 5 minutes ago
loader
loader
Attachment
Mike Chilcote Wow looks like a great move in the acquisition of this new venture. Always forward Raymond. Good work 3 hours 13 minutes ago
loader
loader
Attachment

Notifications

Events

Sorry, we currently have no events.
View All Events